After performing the first commercial revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) implantation outside of a clinical trial, Charles Wykoff, MD, PhD, director of research at Retina Consultants of Texas, offered a detailed account of how the first year of real-world use has shaped his clinical approach to macular telangiectasia type 2 (MacTel).